Evogene Ltd. (NASDAQ:EVGN) Sees Large Decrease in Short Interest

Evogene Ltd. (NASDAQ:EVGN) saw a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 21,000 shares, a drop of 44.9% from the December 15th total of 38,100 shares. Based on an average daily volume of 291,600 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.4% of the company’s stock are sold short.

Analyst Ratings Changes

Separately, StockNews.com began coverage on shares of Evogene in a research note on Monday. They set a “sell” rating on the stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC bought a new position in Evogene Ltd. (NASDAQ:EVGN) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is owned by hedge funds and other institutional investors.

Evogene Price Performance

Shares of EVGN traded down $0.03 during trading hours on Tuesday, hitting $1.52. 13,947 shares of the company were exchanged, compared to its average volume of 41,668. The firm has a fifty day simple moving average of $1.63 and a 200-day simple moving average of $3.04. The company has a market capitalization of $8.15 million, a PE ratio of -0.34 and a beta of 1.30. Evogene has a one year low of $1.20 and a one year high of $10.40.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.